Peptide Education Manager
Edit GLP-3R
Name
Scientific / Common Name
Alternative Names
Slug (url-safe, unique)
Short Description (shown on cards)
A metabolic health therapy built on retatrutide, an investigational triple-receptor compound currently being studied in human clinical trials.
Overview — What Is It? (paragraphs)
GLP-3R is Elan Vital RX's product name for a formulation built on retatrutide, an investigational compound that activates three separate hormone receptors involved in metabolism: GIP, GLP-1, and the glucagon receptor. Retatrutide has not received FDA approval and remains in active human clinical trials studying its effects on body weight and metabolic markers. Because retatrutide is still investigational, the evidence base is earlier-stage than for already-approved metabolic therapies. Published Phase 2 trial results have shown measurable effects in trial participants, but the compound has not completed the full regulatory approval process. GLP-3R, as offered by Elan Vital RX, is this company's own product name and is not an FDA-approved branded drug product.
Why Being Studied (one item per line)
Triple incretin and glucagon receptor activation Body weight and fat mass reduction Insulin sensitivity Energy expenditure signaling
How It May Work
Retatrutide is designed to activate the GIP receptor, GLP-1 receptor, and glucagon receptor simultaneously. Researchers have proposed that adding glucagon receptor activity to the GIP/GLP-1 mechanism may further influence energy expenditure and fat metabolism, in addition to the appetite and blood-sugar effects associated with GIP/GLP-1 activation alone.
Mechanism Pathway Steps (one per line)
Retatrutide (investigational active ingredient) GIP, GLP-1 & glucagon receptor activation Appetite, insulin & energy expenditure pathways Metabolic outcomes under active clinical investigation
Evidence Rating
Established / Approved Use
Strong Human Evidence
Moderate Human Evidence
Early Human Evidence
Preclinical Evidence
Emerging / Limited Evidence
Human Evidence
Retatrutide has been studied in published Phase 2 randomized clinical trials examining body weight and metabolic markers in human participants. As of this writing, it has not completed Phase 3 trials or received FDA approval.
Preclinical Evidence
Preclinical pharmacology studies characterized retatrutide's receptor activity across GIP, GLP-1, and glucagon pathways prior to human trials.
What We Don't Know Yet
Long-term safety and efficacy data from completed Phase 3 trials and regulatory review are not yet available. GLP-3R as a specific Elan Vital RX formulation has not undergone independent clinical trials of its own.
Research Area Cards (format: Title: description — one per line)
Metabolic Health: Triple-receptor activation is being studied for its combined effects on blood sugar and energy metabolism. Weight Management: Published trial data has examined body weight changes in study participants over defined trial periods.
Why Might Someone Discuss This With Their Provider?
Someone following emerging metabolic research may encounter GLP-3R while researching next-generation incretin and glucagon receptor therapies.
Regulatory Status
Retatrutide, the active investigational compound represented by GLP-3R, has not received FDA approval. GLP-3R is Elan Vital RX's own product name and is not an FDA-approved branded drug product.
Important Considerations
Because retatrutide remains investigational, the evidence base is earlier-stage than for already-approved therapies. Side effects observed in trials have included gastrointestinal symptoms. Discuss candidacy and risks with a licensed healthcare provider.
Related Peptide Slugs (one per line)
glp-2t mots-c
Is Combination Product?
Categories / Goals
Recovery & Repair
Metabolic Health
Weight Management
Performance
Muscle & Body Composition
Sleep & Recovery
Cognitive Health
Stress & Mood
Longevity & Healthy Aging
Cellular Energy
Skin, Hair & Aesthetics
Sexual Wellness
Search Tags (comma separated)
Last Reviewed Date
Display Order
Published
Featured
Save Peptide